CRISPR Gene Therapy: From Laboratory to Clinic

⚖ RESOLUTION: FDA approved Casgevy with post-market surveillance requirements for off-target monitoring. Current consensus: off-target rates with approved therapies are at or below spontaneous mutation rates, but long-term monitoring remains essential. Base editing and prime editing further reduce concerns by avoiding double-strand breaks.

⚖ RESOLUTION: He Jiankui was sentenced to 3 years in prison (December 2019). The global scientific community has near-unanimously condemned the experiment. The children (now ~8 years old) remain under Chinese government protection with unknown health status. The episode has become a defining negative case study in research ethics and accelerated calls for international governance of germline editing.

⚖ RESOLUTION: Current international consensus (WHO, National Academies, ISSCR): clinical germline editing should not proceed until safety and efficacy can be established, societal consensus is achieved, and rigorous oversight mechanisms exist. Basic research on human embryos continues to be permitted in some jurisdictions (UK, China, US with restrictions). The debate is active and ongoing.

⚖ RESOLUTION: Ongoing split: Broad Institute controls dominant US patents for eukaryotic (human cell) CRISPR editing; UC Berkeley holds European foundational patents. Commercial agreements have been reached with different companies licensing from different entities. The patent war has not been fully resolved and continues to affect biotech licensing dynamics globally.

⚖ RESOLUTION: Deeply contested. US Medicaid programs are negotiating outcomes-based agreements. Global access remains minimal. Novartis and other companies have announced tiered pricing approaches for low-income countries for other gene therapies. WHO and patient groups are actively lobbying for innovative payment models (annuity-based, outcomes-linked) for CRISPR therapies globally.

⚖ RESOLUTION: Current scientific consensus leans toward Casgevy as functionally curative for most treated patients based on available evidence. However, the FDA requires 15 years of post-market follow-up. Longer-term data (10+ years) will be critical for definitively confirming durability and detecting rare late adverse events.

⚖ RESOLUTION: Both paradigms have clear applications and limitations. Ex vivo dominates for blood/immune disorders where cells can be harvested. In vivo is essential for non-blood diseases (liver, lung, CNS, muscle). The field is pursuing both in parallel, with in vivo seen as the longer-term scalable approach once delivery challenges for non-liver tissues are solved.

⚖ RESOLUTION: China has strengthened its gene editing and clinical trial regulations significantly since 2019 (National Ethical Review Measures for Medical Scientific Research 2023). International oversight gaps remain, and no global treaty binds nations to common CRISPR research standards. WHO's governance recommendations are voluntary.

⚖ RESOLUTION: No gene drives have been released into wild populations as of 2026. Contained field trials with non-propagating modified mosquitoes are underway in Mali and other countries under strict biosafety protocols. International governance bodies, including the UN Convention on Biological Diversity, continue deliberating on frameworks for gene drive governance. Research continues with broad scientific consensus that contained lab and small-scale field studies are appropriate, but open environmental release requires much stronger governance.

⚖ RESOLUTION: Deep access inequality exists. WHO has called for tiered pricing. Some manufacturers have announced access programs for specific low-income countries. Global health organizations are funding lower-cost CRISPR therapy development (e.g., NIH's HEAL initiative, Sickle Cell Disease Coalition). Base editing and in vivo approaches may eventually enable lower-cost treatments, but equitable access remains an unsolved structural problem.

⚖ RESOLUTION: Both technologies are advancing in parallel. Base editing has a near-term clinical lead. Prime editing is likely the more complete long-term solution but faces additional delivery challenges (larger payload size). The field may see base editing achieve first regulatory approvals while prime editing addresses a broader disease spectrum thereafter.

⚖ RESOLUTION: CRISPR diagnostics proved the technology platform beyond therapeutics and secured FDA EUAs. PCR remains the regulatory gold standard for clinical diagnostics. CRISPR-based diagnostics are now being developed for cancer biomarker detection, antimicrobial resistance surveillance, and emerging pathogen identification — a growing market separate from COVID-19 testing.

⚖ RESOLUTION: LNPs are proven for liver delivery and advancing for lung (inhaled LNPs). Non-liver systemic delivery remains a major unsolved challenge and active research area. The field expects incremental progress — achieving efficacy in specific non-liver compartments (e.g., T-cells, tumor microenvironments, muscle) over the next 5–10 years, but a universal systemic non-liver delivery platform does not yet exist.

⚖ RESOLUTION: No jurisdiction currently permits genetic enhancement editing in humans. Current regulatory frameworks restrict CRISPR therapies to serious diseases where there is clear medical necessity. The boundary is expected to remain contentious as enhancement technologies advance. Most bioethicists support a strong default presumption against enhancement until safety, equity, and consent issues are adequately addressed.

⚖ RESOLUTION: Allogeneic CRISPR CAR-T is advancing but has not yet demonstrated superiority or non-inferiority to autologous CAR-T in randomized trials. Persistence and rejection remain the key barriers. The field expects both to coexist: autologous for best efficacy in B-cell malignancies, allogeneic (if persistence challenges are solved) for speed-critical and dose-intensive applications.